Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;15:5131–5146. doi: 10.2147/IJN.S257084

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ou et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

GP-inhibitors affected miR-214-regulated pathways in osteosarcoma cells. (A) Measurements of miR-214 levels in cells after treatment with lipo-inhibitor or GP-inhibitor. *p < 0.05. (B) Bioinformatic analysis revealed that miR-214 potentially targeted PTEN by the 3ʹ untranslated region (3ʹ‑UTR), and the miR‑214 binding site was conserved among different species. (C) The expression levels of p-PTEN, PTEN, p-Akt, Akt, p-ERK1/2, ERK1/2, cleaved caspase-3 and cleaved caspase-8 after incubation with lipo-inhibitor or GP inhibitor were evaluated by Western blotting. (D) Representative immunofluorescence microscopy images of p-PTEN and caspase-3 after incubation with lipo-inhibitor or GP inhibitor. Scale bars: 20 μm.